A Clinical Trial of XZP-6019 Tablets in Healthy Subjects

NCT ID: NCT05063968

Last Updated: 2021-10-01

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-11-30
• Study Completion Date: 2022-09-30

Brief Summary

This study will consist of 3 parts: Part A - Single Ascending Dose (SAD) phase, Part B - Food Effect (FE) phase, and Part C - multiple ascending dose (MAD) phase.

Detailed Description

Part A and Part C studies were designed as single-center, randomized, double-blind, placebo-controlled, dose-escalation trials to assess the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single and multiple oral doses of XZP-6019 tablets in healthy adult subjects. Part B is a single-center, randomized, open label, 2×2 crossover design to assess the food effects on PK of a single oral dose of XZP-6019 tablets in healthy adult subjects.

Conditions

Non-alcoholic Fatty Liver Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part A - Single Ascending Dose (SAD) phase: Experimental

Group Type: EXPERIMENTAL

XZP-6019 tablet

Intervention Type: DRUG

Tablet is administered orally once on Day 1 and Day 9, respectively

Part A - Single Ascending Dose (SAD) phase:Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Tablet is administered orally once on Day 1 and Day 9, respectively

Part B - Food Effect (FE) phase: Experimental 1

Group Type: EXPERIMENTAL

XZP-6019 tablet

Intervention Type: DRUG

Tablet is administered fasted orally once on Day 1

Part B - Food Effect (FE) phase: Experimental 2

Group Type: EXPERIMENTAL

XZP-6019 tablet

Intervention Type: DRUG

Tablet is administered after a high-fat meal orally once on Day 9

Part C - multiple ascending dose (MAD) phase: Experimental

Group Type: EXPERIMENTAL

XZP-6019 tablet

Intervention Type: DRUG

Tablet is administered orally once daily for 14 Days continuously

Part C - multiple ascending dose (MAD) phase:Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Tablet is administered orally once daily for 14 Days continuously

Interventions

XZP-6019 tablet

Tablet is administered orally once on Day 1 and Day 9, respectively

Intervention Type: DRUG

Placebo

Tablet is administered orally once on Day 1 and Day 9, respectively

Intervention Type: DRUG

XZP-6019 tablet

Tablet is administered fasted orally once on Day 1

Intervention Type: DRUG

XZP-6019 tablet

Tablet is administered after a high-fat meal orally once on Day 9

Intervention Type: DRUG

XZP-6019 tablet

Tablet is administered orally once daily for 14 Days continuously

Intervention Type: DRUG

Placebo

Tablet is administered orally once daily for 14 Days continuously

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subjects meeting all of the following criteria will be enrolled in this study.

1. Healthy adult males or females aged 18 to 45 years (including 18 and 45 years old).

2. Body weight ≥ 50 kg for males and ≥ 45 kg for female; body mass index (BMI) in the range of 19.0-26.0 kg/m2 for the non-obese cohort and in the range of 28.1 -35.0 kg/m2 for the obese cohort (including the boundary value, BMI=weight/height2).

3. No plans for childbearing or donating sperm/egg within the latest 6 months, and willing to use effective contraception within 6 months after the end of dosing

4. No clinically significant findings in vital signs, physical examination, laboratory tests, or ECG or Lung CT for Low-dose.

5. Subjects understand and comply with the study procedures, voluntarily participate, and sign an Informed Consent Form.

Exclusion Criteria

• Subjects meeting any of the following criteria will not be enrolled in this study:

1. With history or presence of clinically significant abnormalities, e.g.: significant abnormality or disease of endocrine, gastrointestinal, cardiovascular, hematologic, hepatic, immunologic, renal, respiratory, genitourinary or major neurological (including stroke and chronic epilepsy) or patients with psychosomatic disorders

2. History of clinically significant ECG abnormalities or family history of long QT syndrome (grandparents, parents and siblings), or

Any of the following was regarded as a criterion for exclusion:

1. Confirmation of QTcF ≥ 450 ms by repeated measurements;

2. Confirmation of QRS duration > 120 ms by repeated measurements;

3. Confirmation of PR interval > 200 ms by repeated measurements;

4. Findings that make QTc measurement difficult or QTc data difficult to interpret;

5. History of other risk factors for Torsades de Pointes tachycardia (e.g., heart failure, hypokalemia, family history of long QT syndrome);

6. Presence of uncorrected hypokalemia or hypomagnesemia.

3. Subjects with a known or suspected history of allergy to the test drug or its excipient components, or a history of clinically significant severe allergy (e.g., food, drug, latex allergy), or a history of atopic allergic disease (asthma, urticaria, eczematous dermatitis)

4. History of dysphagia or any gastrointestinal disorder affecting drug absorption at screening, including history of frequent nausea or vomiting of any etiology, history of irregular gastrointestinal motility such as habitual diarrhea, constipation or pre-irritable bowel syndrome, or history of major gastrointestinal surgery (e.g., gastrectomy, gastrointestinal anastomosis, bowel resection, gastric bypass, gastric division, or gastric banding)

5. History of pancreatic injury or pancreatitis at screening, or significantly elevated blood amylase (> 1.5 ULN)

6. History of urinary tract obstruction or presence of urinary voiding difficulties at screening.

7. History of cancer (malignancy) at the time of screening.

8. Positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or syphilis antibody

9. History of significant drug abuse within 12 months prior to screening or positive urinary drug test at screening

10. Regular alcohol consumption within 3 months prior to screening, consuming more than 3 alcoholic drinks per day (one drink is approximately equal to: beer 354 mL/12 oz, wine 118 mL/4 oz, or distilled spirits 29.5 mL/1 oz), or evidence of alcohol abuse and excessive consumption as evidenced by alcohol breath test at screening (subjects consuming 4 alcoholic drinks per day may be enrolled at the discretion of the investigator).

11. History of smoking within 3 months prior to screening, or a positive urinary nicotine test at screening, or who cannot give up smoking throughout the study period

12. Excessive daily intake of coffee, tea, cola, energy drinks, or other caffeinated beverages within 3 months prior to screening, with excess defined as more than 6 servings (one serving is approximately equal to 120 mg of caffeine).

13. Major surgery, or donation or loss of blood over 400 mL within 3 months prior to administration.

14. Participation in other clinical trials and treatment with investigational product within 3 months prior to administration.

15. Take any prescription, over-the-counter, health product, herbal or proprietary Chinese medicine within 4 weeks prior to administration (or less than 5 half-lives of the drug administration from the start of the trial).

16. Women who are pregnant or breastfeeding, or of childbearing potential who are not using effective non-hormonal contraception (intrauterine device (IUD), barrier method with spermicide, or surgical sterilization, etc.) or are unwilling to continue using these methods during the trial until 6 months after discontinuation; men of childbearing potential who are unwilling to use physical methods of contraception during the trial until 6 months after discontinuation.

17. At the time of screening, Systolic blood pressure ≥ 140 mmHg or < 90 mmHg, and/or diastolic blood pressure ≥ 90 mmHg or < 50 mmHg.

18. At the time of screening, Heart rate < 50 or > 100 beats/min.

19. Glomerular filtration rate (eGFR) < 90 ml/min/1.73m2 was estimated at screening according to the Chronic Kidney Disease Epidemic (CKD-EPI) formula (see Annex 1 for calculation formula).

20. At screening, the liver function tests showed any measure of aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) or total bilirubin is > upper limit of normal (ULN) in non-obesity cohorts; liver function tests of obese group showed AST, ALT or ALP is > 1.5 ULN, or total bilirubin is > ULN in obesity cohort.

21. Fasting triglycerides > 2.3mmol/L at the time of screening.

22. Fasting glucose > 5.6 mmol/L in the non-obese cohort and > 6.1 mmol/L or glycosylated hemoglobin (HbA1c) ≥ 6.5% in the obese group at screening.

23. Those who could not tolerate blood sample collection.

24. Subjects who are deemed by the investigator to be unsuitable for participation in the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Xuanzhu Biopharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ruihua Dong, Doctor

Role: PRINCIPAL_INVESTIGATOR

Beijing Friendship Hospital

Locations

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Countries

China

Central Contacts

Jingjing Wu

Role: CONTACT

wujingjing@xuanzhupharm.com

+86-010-57654511

Facility Contacts

Ruihua Dong, Doctor

Role: primary

Ruihua_Dong_RW@163.com

+86-13810461342

Other Identifiers

6019-CPK-1001

Identifier Type: -

Identifier Source: org_study_id